(Q42801121)

7 November 2017

title

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial (English)

1 reference

7 November 2017

1 reference

1 reference

1 reference

5

1 reference

7 November 2017

Ivana Sestak

2

0 references

Mitch Dowsett

series ordinal

6

object named as

Mitch Dowsett

1 reference

7 November 2017

1

Jack Cuzick

1 reference

7 November 2017

4

Aman Buzdar

1 reference

7 November 2017

Michael Baum

3

1 reference

7 November 2017

John F Forbes

series ordinal

7

1 reference

7 November 2017

ATAC/LATTE investigators

series ordinal

8

1 reference

7 November 2017

publication date

17 November 2010

1 reference

Lancet Oncology Commission

7 November 2017

published in

1 reference

7 November 2017

volume

11

1 reference

7 November 2017

issue

12

1 reference

7 November 2017

page(s)

1135-1141

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Update of the BIG 1-98 Trial: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970257-6

7 January 2021

10.1016/S1470-2045(10)70257-6

Identifiers

DOI

1 reference

7 November 2017

1 reference